Research
Hormonal
New generation incretin analogues (semaglutide 2.4 mg weekly and tirzepatide 5-15 mg weekly) produce sustained mean weight reductions of 15-20% in adults with BMI ≥27 kg/m², significantly outperforming older agents and lifestyle interventions alone.
If you have a BMI over 27, talk to your doctor about semaglutide or tirzepatide. These are weekly injections (or oral pills for semaglutide) that help you lose 15-20% of your body weight, which is much more than older drugs. You must also follow a lifestyle plan with diet and exercise.
StrongSupportsVERY_HIGH confidence
The new generation of agents, including the injectable incretin analogues semaglutide and tirzepatide are associated with sustained mean weight reductions of 15–20%, along with substantial benefits on a range of health outcomes.
Why this rating
Based on Phase 3 RCTs (STEP 1, SURMOUNT 1) with large sample sizes (N>1900-2500) and long duration (68-72 weeks).
Source
Obesity medications: A narrative review of current and emerging agents
Qi Q et al. · Osteoarthritis and Cartilage Open · 2024
narrative_reviewCited 20×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →